| |
|
Product Name:
|
Zika virus, R116265 (Human/2016/Mexico)
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Flaviviridae, Flavivirus
Species: Zika virus
Strain/Isolate: R116265
|
|
Additional Information:
|
ZIKV is a member of the Spondweni serocomplex of mosquito-borne flaviviruses. ZIKV is vectored primarily by Aedes spp., but has also been isolated from Anopheles, Eretmapodites, and Mansonia mosquitoes.3 Phylogenetic analyses indicated that there are two major lineages of ZIKV, African and Asian.4 A third lineage circulating in West Africa was recently described.5 The first human infections with ZIKV were reported in Nigeria in 1954.6 Only sporadic infections were seen until 2007, when a large outbreak occurred in Yap State, Federated States of Micronesia.7 There was another large outbreak in French Polynesia in 2013, concomitant with a Dengue fever epidemic, and the virus has subsequently spread throughout the South Pacific.8,9,10,11,12,13 Autochthonous transmission of ZIKV in Brazil was reported early in 2015, and has since been reported in countries throughout Central America and the Caribbean.14,15 It seems likely that the Asian lineage of ZIKV was introduced into Brazil by travelers from one or more Pacific Island countries.16 The outbreak in the Americas has become the most widespread in history. Updates on areas with ongoing ZIKV transmission are available online from the Centers for Disease Control and Prevention.17 An estimated 80% of human ZIKV infections are asymptomatic, and symptomatic disease is generally mild and characterized by fever, maculopapular rash, arthralgia, and non-purulent conjunctivitis. However, ZIKV infections were confirmed in infants with microcephaly, and outbreaks in Brazil and elsewhere have been accompanied by a marked increase in the number of children born with microcephaly, and sufficient evidence has since accumulated to infer a causative relationship between prenatal ZIKV infection and microcephaly and other severe brain anomalies.18,19,20,21 The full teratogenic potential of ZIKV, the absolute and relative risks among infants exposed to ZIKV in utero, and factors that may modify these risks remain to be determined.
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from Chlorocebus aethiops kidney epithelial cells (Vero; ATCC® CCL-81™) infected with ZIKV, R116265.
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-50551 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: Chlorocebus aethiops kidney epithelial cells (Vero; ATCC® CCL-81™)
Growth Medium: Eagle’s Minimum Essential Medium containing Earle’s Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine and 1 mM sodium pyruvate supplemented with 2% fetal bovine serum, or equivalent
Infection: Cells should be 80% to 95% confluent
Incubation: 4 to 8 days at 37°C and 5% CO2
Cytopathic Effect: Cell rounding and detachment
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Russell, B. J. Personal Communication.
2. Lanciotti, R. S. Diagnostic and Reference Laboratory, Arbovirus Diseases Branch, Centers for Disease Control and Prevention, 3150 Rampart Road, Fort Collins, Colorado 80521, USA. Direct submission.
3. Grard, G., et al. “Genomics and Evolution of Aedes-Borne Flaviviruses.” J. Gen. Virol. 91 (2010): 87-94. PubMed: 19741066.
4. Haddow, A. D., et al. “Genetic Characterization of Zika Virus Strains: Geographic Expansion of the Asian Lineage.” PLoS Negl. Trop. Dis. 6 (2012): e1477. PubMed: 22389730.
5. Berthet, N., et al. “Molecular Characterization of Three Zika Flaviviruses Obtained from Sylvatic Mosquitoes in the Central African Republic.” Vector Borne Zoonotic Dis. 14 (2014): 862-865. PubMed: 25514122.
6. McNamara, F. N. “Zika Virus: A Report on Three Cases of Human Infection During an Epidemic of Jaundice in Nigeria.” Trans. R. Soc. Trop. Med. Hyg. 48 (1954): 139- 145. PubMed: 13157159.
7. Lanciotti, R. S., et al. “Genetic and Serologic Properties of Zika Virus Associated with an Epidemic, Yap State, Micronesia, 2007.” Emerg. Infect. Dis. 14 (2008): 1232- 1239. PubMed: 18680646.
8. Cao-Lormeau, V. M., et al. “Zika Virus, French Polynesia, South Pacific, 2013.” Emerg. Infect. Dis. 20 (2014): 1085-1086. PubMed: 24856001.
9. Baronti, C., et al. “Complete Coding Sequence of Zika Virus from a French Polynesia Outbreak in 2013.” Genome Announc. 2 (2014): e0050014. PubMed: 24903869.
10. Heang, V., et al. “Zika Virus Infection, Cambodia, 2010.” Emerg. Infect. Dis. 18 (2012): 349-351. PubMed: 22305269.
11. Pyke, A.T., et al. “Imported Zika Virus Infection from the Cook Islands into Australia, 2014.” PLoS Curr. 6 (2014): ecurrents.outbreaks.4635a54dbffba2156fb2fd76dc49f65 e. PubMed: 24944843.
12. Dupont-Rouzeyrol, M., et al. “Co-Infection with Zika and Dengue Viruses in 2 Patients, New Caledonia, 2014.” Emerg. Infect. Dis. 21 (2015): 381-382. PubMed: 25625687.
13. Tognarelli, J., et al. “A Report on the Outbreak of Zika Virus on Easter Island, South Pacific, 2014.” Arch. Virol. First online 26 Nov 2015. PubMed: 26611910.
14. Zanluca, C., et al. “First Report of Autochthonous Transmission of Zika Virus in Brazil.” Mem. Inst. Oswaldo Cruz 110 (2015): 569-572. PubMed: 26061233.
15. Campos, G. S., A. C. Bandeira, and S. I. Sardi. “Zika Virus Outbreak, Bahia, Brazil.” Emerg. Infect. Dis. 21 (2015): 1885-1886. PubMed: 26401719.
16. Musso, D. “Zika Virus Transmission from French Polynesia to Brazil.” Emerg. Infect. Dis. 21 (2015): 1887. PubMed: 26403318.
17. wwwnc.cdc.gov/travel/page/zika-travel-information
18. CDC. “CDC Health Advisory: Recognizing, Managing, and Reporting Zika Virus Infections in Travelers Returning from Central America, South America, the Caribbean and Mexico.” Atlanta, Georgia: US Department of Health and Human Services, CDC. 2016. http://emergency.cdc.gov/han/han00385.asp.
19. Mlakar, J., et al. “Zika Virus Associated with Microcephaly.” New Engl. J. Med. 374 (2016): 951-958. PubMed: 26862926.
20. European Centre for Disease Prevention and Control. “Rapid Risk Assessment. Zika Virus Epidemic in the Americas: Potential Association with Microcephaly and Guillain-Barre´ Syndrome.” Stockholm, Sweden: European Centre for Disease Prevention and Control. 2015. http://ecdc.europa.eu/en/publications/Publications/zika?virus-americas-association-with-microcephaly-rapid-risk-assessment.pdf
21. Rasmussen, S. A., et al. “Zika Virus and Birth Defects – Reviewing the Evidence for Causality.” New Engl. J. Med. 374 (2016): 1981-1987. PubMed: 27074377.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Zika Virus, R116265, NR-50551."
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|